Over the past 5 years we have recognized a new pulmonary complication of hematopoietic stem cell transplantation (HSCT) associated with fever and pulmonary nodules termed 'pulmonary cytolytic thrombi' (PCT). Retrospective analysis of medical and radiographic records and pathologic material from 13 HSCT recipients with PCT and a review of the Blood and Marrow Transplant Database for all patients with radiographic evidence of pulmonary nodules or who underwent openlung biopsy from 1 January 1993 to 31 December 1998 (n = 1228) were performed. The median age of patients with PCT was 11.9 years (range, 1.3-29.7 years). All patients developed fever at a median of 72 days (range, 8-343 days) post transplant, followed by pulmonary nodules on chest CT. Eleven patients were receiving therapy for active GVHD (acute, grades I-IV (n = 10); extensive chronic (n = 1) ). Biopsy of the pulmonary nodules revealed a unique pattern of necrotic, basophilic thromboemboli with amorphous material suggestive of cellular breakdown products. This was descriptively labeled 'pulmonary cytolytic thrombi'. Immunohistochemical staining revealed entrapped leukocytes and disrupted endothelium, but was negative for histiocytes. Cultures and immunohistochemical stains were negative for infectious agents. Empiric therapy included systemic corticosteroids (n = 9) and amphotericin (n = 7). Nine patients survive with resolution of PCT at a median follow-up of 1.5 years. Bone Marrow Transplantation (2000) 25, 293-300. Keywords: pulmonary nodules; stem cell transplant; pulmonary complications; cytolytic thrombi Allogeneic stem cell transplantation is used in the treatment of a variety of malignant and non-malignant conditions. The procedure and associated immunosuppression are associated with both infectious and non-infectious complications. Approximately 30-60% of allogeneic stem cell transplant recipients develop pulmonary complications.
Infectious pulmonary complications include bacterial, viral, fungal, mycobacterial and parasitic pathogens. Non-infectious pulmonary complications include diffuse alveolar hemorrhage, pulmonary veno-occlusive disease, thromboembolism, idiopathic pneumonia syndrome, toxicity from chemotherapy or radiation therapy and graft-versushost disease (GVHD). These entities can affect the airways, alveoli and interstitium of the lung and may result in obstruction, restriction and/or diffusion defects. Multiple pulmonary nodules in immunocompromised hosts are generally considered to be fungal in origin, although other infectious and non-infectious causes are seen. [3] [4] [5] [6] [7] [8] Chest radiographs and computed tomography are routinely performed for the evaluation of prolonged fever in transplant recipients. 9 With the advent of high-resolution CT scanning, smaller pulmonary nodules may now be detected. These lesions are frequently evaluated by bronchoalveolar lavage (BAL), transbronchial biopsy or open-lung biopsy. In this paper, we report the clinical, pathologic and radiographic findings in 13 patients undergoing hematopoietic stem cell transplant (HSCT) over a 5-year period at the University of Minnesota with pulmonary nodules that have been given the novel pathologic diagnosis of 'pulmonary cytolytic thrombi'. 10 We believe that this represents a previously unrecognized pulmonary complication of bone marrow transplantation seen almost exclusively in children that is non-infectious, intravascular, and may be associated with GVHD.
Patients and methods

Patients
Since the identification of the first patient with pulmonary cytolytic thrombi (PCT) in 1993, 12 additional patients have been diagnosed with this condition. These 13 patients underwent related donor (n = 6) or unrelated donor (n = 7) HSCT at the University of Minnesota between 1 January 1993 and 31 December 1998. Patient characteristics are presented in Table 1 . All patients or their guardians signed consents for the transplant procedure which had been approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota. 
Bone Marrow Transplantation
Supportive care
Patients were hospitalized in private rooms with highefficiency particulate air filtration. Antibiotic prophylaxis with trimethoprim-sulfamethoxazole was administered before the development of fever. At the onset of fever, patients received empiric broad-spectrum anti-bacterial and anti-fungal agents. Those patients who were seronegative for cytomegalovirus (CMV) received blood products from seronegative donors, or blood products were filtered to remove contaminating leukocytes. Patients seropositive for CMV or herpes simplex virus received acyclovir prophylaxis.
Graft-versus-host disease (GVHD)
GVHD was diagnosed and graded by standard criteria. 11, 12 GVHD prophylaxis consisted of cyclosporine A (CsA) and methotrexate 13 (n = 9), T cell depletion by counterflow elutriation 14 (n = 2), methotrexate alone (n = 1), or CsA alone (n = 1).
Medical evaluation and chart review
Medical records and radiologic examinations were reviewed for the 13 patients with the diagnosis of PCT. Additionally, a review of the Blood and Marrow Transplant Database at the University of Minnesota was performed to gather clinical and pathologic data on all patients undergoing HSCT from 1 January 1993 to 31 December 1998 (n = 1228). The number and diagnosis of patients with pulmonary nodules as documented by chest radiograph and/or chest CT and the number of patients who underwent open lung biopsy were determined. All 13 patients with PCT had chest CT scans and 12 patients had chest radiographs. These were reviewed for location and measurement of nodules by one observer (SH). All patients with pulmonary nodules underwent open-lung biopsy, except for one patient who was diagnosed with PCT at the time of autopsy. One patient found to have PCT prior to death also underwent autopsy.
Pathologic review
Eleven open-lung biopsies, including two performed at different times on one patient, and two autopsies were performed at this institution. Bacterial, viral and fungal cultures were obtained at the time of biopsy. Two biopsies were performed at other institutions and reviewed at this institution. All tissues were fixed in 10% formalin. After paraffin embedding, 5 m sections were stained with hematoxylin and eosin (H&E). Gomori-Methenamine Silver, acid-fast, Gram, and elastic tissue stains were performed in all patients. In five cases, immunohistochemical stains were performed using antibodies to CD31 (Dako, Carpinteria, CA, USA; 1:20), CD45 (Ventena, Tucson, AZ, USA; no dilution), and CD68 (Dako, 1:50). All pathologic material, including the two biopsies performed at other institutions, was reviewed by one pathologist (EG).
Results
Review of the Blood and Marrow Transplant Database at the University of Minnesota from 1 January 1993 to 31 December 1998 revealed 1228 patients who underwent HSCT. A search of these records revealed 88 patients (7%) with 90 separate radiographic episodes of pulmonary nodules after HSCT, leading to 37 open-lung biopsies (42%) and two autopsies. A list of diagnoses is given in Table 2 . Thirteen patients received the pathologic diagnosis of PCT which represents the leading pathologic diagnosis in patients with pulmonary nodules who underwent open-lung biopsy (29.5%). Additional significant categories included Aspergillus species (18.2%), non-interstitial pneumonitis (11.4%), negative or non-diagnostic (9.1%), and obliterative bronchiolitis (6.8%). Those patients who underwent open-lung biopsy did so because of persistent fever and pulmonary nodules or opacities on chest CT. Gross examination of the lung biopsy material showed firm, relatively well-circumscribed, hemorrhagic lesions. Microscopically, vascular thromboemboli were always present adjacent to the area of hemorrhage but were not restricted to these areas. These nodules had a unique appearance of necrotic, basophilic thromboemboli with amorphous material suggestive of cellular breakdown products ( Figure 1 ). Cultures and immunohistochemical stains were negative for bacterial, viral, fungal and mycobacterial pathogens. Five specimens stained for the endothelial marker CD31 revealed discontinuity of the endothelial cell layer. In cases with ruptured endothelium, the basophilic material infiltrated adjacent lung tissue. Recognizable leukocytes and cell fragments trapped within the basophilic material stained positively for CD45. Few cells were immunoreactive with the histiocytic marker CD68. In one patient who subsequently died, areas of perivascular inflammation, focal endothelitis, and chronic active bronchiolitis were also seen. One patient diagnosed with PCT at autopsy also demonstrated CMV pneumonitis and diffuse alveolar damage.
The median age of the group was 11.9 years (range, 1.3-29.7 years). There were 10 males and three females. Patient characteristics, diagnoses, and remission status for the leukemias are listed in Table 1 . Ten patients were transplanted for malignancy and three patients for non-malignant diagnoses. There were six unrelated donor transplant recipients (one mismatched bone marrow, one mismatched umbilical cord blood, four fully matched at HLA-A and B serologically, and DR␤1 by high-resolution molecular typing). Six patients received matched sibling donor transplants (five genotypically matched, one mismatched at HLA-B). The median cell dose was 2 × 10 8 total nucleated cells/kg (range, 1.86-3.0) for unmanipulated bone marrow and 0.38 × for a median of 3 days (range, 1-8 days) prior to the diagnosis of PCT. Two patients had cough as a predominant symptom. Three patients complained of pain in the shoulder (n = 2), rib (n = 1) or chest (n = 1). One patient reported sinus drainage and pain, while one patient had clear rhinorrhea. Ten patients (77%) had active acute GVHD at the time PCT developed (Table 3 ). All patients were receiving corticosteroids and cyclosporine, with one patient (UPN 2904) also receiving monoclonal antibody treatment (ABX-CBL, Abgenix, Fremont, CA, USA) 15 for GVHD at the time of PCT. Two additional patients (UPN 1915 and 2402) had recently resolved acute GVHD. One patient (UPN 1915) subsequently developed acute GVHD of the liver 2 weeks after the diagnosis of PCT and one patient (UPN 2402) subsequently developed limited chronic GVHD 2 weeks after the diagnosis of PCT. One patient (UPN 1802) had extensive chronic GVHD at the time of PCT. Three patients had other conditions present at the time of PCT including microangiopathic hemolytic anemia, pericardial effusion, disseminated intravascular coagulation and Guillain-Barre syndrome.
Because of unexplained fever, all patients were evaluated for potential pulmonary infiltrates by chest radiograph and/or chest CT. A chest radiograph was obtained in 12 of 13 patients. Nine patients had abnormal chest radiographs (Table 4 ). Chest radiographic findings included possible or definite opacities or nodules (n = 6), normal (n = 4), interstitial prominence (n = 2) and atelectasis (n = 1). All patients underwent computed tomography (CT) of the chest after a median of 3 days of fever (range, 1-8 days). Chest CT revealed pulmonary parenchymal and pleural nodules of variable size (few mm to 4 cm) in all but one patient (UPN 2697). These nodules were predominantly peripheral and/or basilar in 10 patients (Figure 2 ). UPN 2697 demonstrated a unique pattern of extensive air-space opacities.
After abnormal CT results were obtained, five patients underwent bronchoalveolar lavage (BAL) 1-2 days later. BAL was abnormal in three patients. One patient demonstrated numerous lipid-laden and hemosiderin-laden macrophages consistent with either aspiration pneumonitis, previous pulmonary hemorrhage, non-specific lung injury or a combination of those entities. In a second patient, both Pseudomonas and Candida species were isolated. A third patient had normal flora (Micrococcus species) isolated from BAL fluid.
Twelve patients with pulmonary nodules underwent open-lung biopsy a median of 1 day after chest CT (range, 0-5 days). In the one patient who did not undergo openlung biopsy, the diagnosis was made at autopsy. Three patients had two biopsies each. One patient previously diagnosed with PCT underwent subsequent autopsy (UPN 2697).
Necropsy samples in the two patients undergoing autopsy included multiple sections taken from the lungs. All patients received the pathologic diagnosis of PCT based on morphologic appearance and exclusion of known infectious agents. Cultures from the biopsy specimens were negative in 11 cases. Two patients had positive cultures from the lung biopsy, including coagulase-negative Staphylococcus and Bacillus species isolated in one patient, both of which may represent contaminants.
In 46% (6/13) of the 13 patients, pathogens were isolated from non-pulmonary sites a median of 4 days before (range, 116 days before to 6 days after) the diagnosis of PCT (Table 5 ). Ten pathogens were isolated in these six patients: five viruses, four bacteria and one fungal species. The five viral infections included cutaneous varicella-zoster (n = 2), CMV retinitis, influenza A upper respiratory tract infection, and parainfluenza upper respiratory tract infection. CMV retinitis, influenza A, and parainfluenza all occurred in the patient with Wiskott-Aldrich syndrome (UPN 2697). Influenza A and CMV were diagnosed 3 months prior to the patient's death but remained active at the time of death. The bacterial infections included Eschericia coli urinary tract infection and coagulase-negative Staphylococcus bacteremia. One fungal infection occurred, cutaneous Aspergillus fumigatus isolated from a skin biopsy.
All patients received broad-spectrum antibiotics. Ten of 13 patients received empiric amphotericin B. In two patients, amphotericin was discontinued within 3 days when stains were negative for fungal pathogens. Two patients also received itraconazole in conjunction with amphotericin B for presumed pulmonary aspergillosis despite their negative lung biopsy. Five patients received corticosteroids concomitantly for active acute or chronic GVHD. One patient was treated with coumadin.
In the majority of patients clinical improvement was evident within 1-2 weeks, and radiologic improvement occurred over weeks to months. Nine of 13 (69%) patients survive. The four deaths were attributed to: relapse (one), multi-organ failure (two) and infection (one) from 0 to 11 months after the diagnosis of PCT. One of the patients who died 9 months after open-lung biopsy, had an earlier CT scan demonstrating resolution of pulmonary nodules. Another patient who died 4 months after open-lung biopsy had an autopsy demonstrating Aspergillus species but no findings of PCT at autopsy. Therefore, two of the four patients with PCT who died had no evidence of PCT at the time of death. Table 4 Radiographic findings in pulmonary cytolytic thrombi 
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Discussion
Bone marrow transplantation is associated with various infectious and non-infectious pulmonary complications. In immunocompromised patients, multiple pulmonary nodules are generally considered to be infectious, predominantly fungal. 2, 3, 5 Prior to neutrophil engraftment, pulmonary nodules are most commonly due to Aspergillus or other fungal species. 16 Fungal pneumonias due to Aspergillus or less common pathogens may also be seen later in the transplant course of patients receiving corticosteroids. 17, 18 Viral pneumonias caused by cytomegalovirus or other viruses may appear nodular; 19 bacterial and mycobacterial pneumonias may give a similar nodular appearance. 20 Additionally, noninfectious entities associated with a nodular appearance include metastatic tumor, post-transplant lymphoproliferative disorder, hypercalcemia, early bronchiolitis obliterans, and thromboembolic phenomena due to sepsis, fat embolism, or hypercoagulable state. 2, 3, 16, 21, 22 All of these entities have a characteristic histologic appearance distinct from what we describe in PCT.
We have identified a subset of bone marrow transplant patients with pulmonary nodules due to a newly described entity, pulmonary cytolytic thrombi. Although it is possible that these lesions may represent an infectious agent which was not cultured or observed histologically, the pathologic appearance of these nodules is unique and bears no resemblance to other infectious or non-infectious entities. Although the majority of the patients received amphotericin B for presumed pulmonary fungal nodules, several of the patients received treatment for only 2-3 days, which is not sufficient therapy for eradication of disseminated pulmonary fungal disease. Given that fungal pathogens were not detected by culture, immunohistochemical stains and routine histology, it is unlikely that pulmonary fungal infections were present. The patient with Aspergillus in the lungs at autopsy had a previous lung biopsy with PCT that did not demonstrate fungus. The autopsy revealed no histologic evidence of PCT. The nodules do not appear similar to either fat emboli, septic emboli or typical vascular thromboemboli. Granulocyte transfusions have been associated with pulmonary complications; however, no patients received granulocyte transfusions prior to development of PCT. Although total parenteral nutrition has been associtaed with the development of pulmonary nodules, these nodules are lipid in origin and are associated with granulomatous arteriolitis, features absent in our cohort. Posttransplant lymphoproliferative disorder (PTLD) may have isolated intrathoracic nodules; however, it has a characteristic histologic appearance and is more commonly associated with adenopathy and multi-organ involvement. 23 None of the PCT patients received therapy for PTLD and, in fact, several of the patients received increased immunosuppression for their GVHD, which would have exacerbated PTLD.
Eleven of the 13 patients (85%) with PCT had active acute or chronic GVHD. One patient (UPN 2784) also had obliterative bronchiolitis diagnosed at the same time as PCT. Of the remaining two patients without active GVHD, one had previous acute GVHD of the skin and one subsequently developed liver GVHD. The association of PCT with GVHD leads us to speculate that these lesions are cellular inflammatory lesions due to the immune dysregulation of GVHD. Inflammatory pneumonitis is well-documented after BMT and includes a spectrum of disease from lymphocytic interstitial pneumonitis (LIP) to bronchiolitis obliterans. 1, 24, 25 Interestingly, in our cohort, only two patients (UPN 2784 and UPN 1897) demonstrated inflammation in pathologic samples of lung tissue in addition to PCT. UPN 2784 also had obliterative bronchiolitis. Vascular thromboemboli are not described with LIP or obliterative bronchiolitis. Entrapped leukocytes were recognized by the CD45 stain. Additional immunohistochemical stains for CD4 and CD8 were unsuccessful. Some cases of PCT showed evidence of endothelial disruption by CD31 staining. We speculate that part of the pathophysiology of PCT includes endothelial injury. Future cases of PCT will undergo additional immunohistochemical and molecular testing to further characterize the cellular thromboemboli.
Although not proven at present, leukocytes in PCT are unlikely to represent hematopoietic progenitors given the length of time after BMT. PCT appears to be restricted to allogeneic stem cell transplantation, as no cases have been seen in patients receiving autologous or syngeneic stem cells. Similarly, we have not observed PCT in recipients of solid-organ transplants. Of interest is the fact that several patients showed clinical improvement and radiologic resolution of their pulmonary nodules after increased immunosuppression was administered.
Other possible etiologies of PCT include chemotherapy or radiotherapy-induced pulmonary toxicity. In the late stages, drug-induced lesions may occasionally have a reticular nodular appearance and may improve with corticosteroids. 26 If therapy-related toxicity were the cause of PCT, we would expect cases in patients undergoing autologous transplantation or patients receiving high-dose chemotherapy without stem cell support. To date, no such cases have been identified at our institution.
Ten of the 13 specimens demonstrated areas of hemorrhage adjacent to the PCT, although clinically, no patient had a previous history of pulmonary hemorrhage. Interestingly, the areas of hemorrhage were restricted to areas of PCT. Pulmonary infarcts or thromboemboli have not been described in diffuse alveolar hemorrhage. Venous or arterial thromboemboli are infrequently identified in BMT recipients. Case reports of pulmonary emboli after BMT have described calcified thromboemboli with non-specific interstitial and alveolar inflammatory infiltrates. 27 Endothelial swelling and thrombi have also been described in pulmonary arterioles, capillaries, and venules of deceased BMT patients undergoing autopsy and were associated with interstitial pneumonitis and pulmonary hemorrhage. 28 PCT may represent one aspect of this spectrum of pulmonary disease after HSCT.
The relative insensitivity of chest radiographs for detecting multiple pulmonary nodules in BMT patients with prolonged fevers underscores the utility of high-resolution chest CT scanning in these patients. Only nine of the 13 patients had abnormal chest radiographs. Furthermore, the abnormal chest radiograph frequently showed only nonspecific changes rather than discrete nodules, while highresolution chest CT revealed nodules in all cases.
Several of the patients underwent bronchoalveolar lavage in an attempt to isolate a pathogen. In no case was a definitive diagnosis made. This is likely due to the peripheral location and intravascular nature of the nodules. Open-lung biopsy has been reported to have increased diagnostic sensitivity for infectious and non-infectious diagnoses over bronchoalveolar lavage in immunocompromised patients 29 and this was confirmed in our experience in this group of patients.
A more detailed retrospective analysis of lung biopsy specimens in BMT recipients is underway to determine if specimens prior to 1993 may have demonstrated PCT. It is likely that this entity will be recognized more frequently due to improved imaging modalities and the recognition of the clinical, radiographic and pathologic findings of PCT that we describe here. Until definitive data are available regarding the etiology of PCT, we recommend aggressive evaluation of fever and pulmonary nodules in all stem cell transplant recipients. Although PCT accounted for the larg- 
